Our Products
Loans
Cards
Insurance
Investment
Stock Market
Electronics Mall
CIBIL Score
Knowledge Centre
Academy 
Calculators
Our Services
My Account
Do not call
En
SMS Pharmaceuticals Ltd. Share Price
Day's Range
Day's Range
Low
₹412.80
High
₹429.00
Price Summary
| Previous Close | ₹421.50 |
|---|---|
| Day's Range | ₹412.80 - ₹429.00 |
| Open | ₹417.40 |
| 52 Week Range | ₹207.70 - ₹447.80 |
| Volume | 3,51,944 |
| Market Cap | ₹0.00 |
| Previous Close | ₹421.80 |
|---|---|
| Day's Range | ₹413.70 - ₹429.00 |
| Open | ₹421.95 |
| 52 Week Range | ₹205.30 - ₹446.50 |
| Volume | 8,305 |
| Market Cap | ₹0.00 |
Stocks Summary
| Trade Value ( ₹ in Lacs) | 1,483.44 |
|---|---|
| Market Cap (₹ in Mn) | 0.00 |
| Dividend Yield(%) | 0.10 |
| Price/Earning (TTM) | 43.30 |
| TTM EPS (₹) | 9.57 |
| P/E Ratio | 27.27 |
| Book Value(₹) | 5.15 |
| PAT Margin (%) | 7.96 |
| Face Value (₹) | 1.00 |
| ROCE(%) | 12.55 |
| Trade Value ( ₹ in Lacs) | 35.03 |
|---|---|
| Market Cap (₹ in Mn) | 0.00 |
| Dividend Yield(%) | 0.10 |
| Price/Earning (TTM) | 43.30 |
| TTM EPS (₹) | 9.57 |
| P/E Ratio | 27.27 |
| Book Value(₹) | 5.15 |
| PAT Margin (%) | 7.96 |
| Face Value (₹) | 1.00 |
| ROCE(%) | 12.55 |
Financials
| Particulars | QTR FY (₹ in Millions) | Annual FY (₹ in Millions) |
|---|---|---|
| Net sales | 1733.53 | 7092.63 |
| Expenses | N/A | N/A |
| PBT | 225.32 | 663.32 |
| Operating profit | 0.0 | 0.0 |
| Net profit | 171.72 | 494.25 |
About SMS Pharmaceuticals Ltd.
| Founded | 1987 |
|---|---|
| Managing Director | Ramesh Babu Potluri |
| NSE Symbol | SMSPHARMA |
Peer Comparision
| Stocks Name | Market Cap (Cr)(₹) | Market Price (₹) | 52 Week Low-High (₹) |
|---|---|---|---|
| Sun Pharmaceutical Industries Ltd. | 4,43,972.94 | 1,831.30 | 1,548.00 - 1,548.00 |
| Divi's Laboratories Ltd. | 1,78,025.88 | 6,681.00 | 5,636.50 - 5,636.50 |
| Torrent Pharmaceuticals Ltd. | 1,47,477.60 | 4,351.60 | 3,101.60 - 3,101.60 |
| Lupin Ltd. | 1,11,668.12 | 2,460.50 | 1,836.80 - 1,836.80 |
| Apollo Hospitals Enterprise Ltd. | 1,11,526.57 | 7,820.45 | 6,677.50 - 6,677.50 |
| Cipla Ltd. | 1,10,282.52 | 1,361.00 | 1,165.70 - 1,165.70 |
| Dr. Reddy's Laboratories Ltd. | 1,09,381.80 | 1,307.00 | 1,138.50 - 1,138.50 |
| Max Healthcare Institute Ltd. | 98,852.37 | 1,015.10 | 903.00 - 903.00 |
| Mankind Pharma Ltd. | 97,505.92 | 2,375.40 | 1,909.70 - 1,909.70 |
| Zydus Lifesciences Ltd. | 94,495.43 | 940.10 | 835.50 - 835.50 |
No Records Found
Latest News
SMS Pharmaceuticals informs about newspaper publication
SMS Pharmaceuticals informs about compliance certificate
SMS Pharmaceuticals informs about trading window closure
SMS Pharmaceuticals informs about newspaper publication
Global Longlife Hospital and Research informs about outcome of board meeting
No Records Found
Sign in to Unlock Offers!
We don't SPAM
Frequently Asked Questions
The current share price of SMS Pharmaceuticals Ltd. is ₹421.50 as of 2026-05-07.
The market capitalisation of SMS Pharmaceuticals Ltd. is ₹3,879.07 as of 2026-05-06.
The 1-year return of SMS Pharmaceuticals Ltd. is 0.00% as of 2026-05-07.
The P/E ratio of SMS Pharmaceuticals Ltd. is 27.27 as of 2026-05-07.
The 52-week high and low of SMS Pharmaceuticals Ltd. are ₹447.80 and ₹207.70, respectively, as of 2026-05-07.
People Also Ask
SMS Pharmaceuticals Ltd. partners with the pharma sector by acting as a highly reliable, large-scale contract manufacturer. The enterprise collaborates with major global and domestic pharmaceutical companies to supply cost-effective, high-quality bulk drugs and pharmaceutical intermediates.
SMS Pharmaceuticals Ltd. produces a critical range of Active Pharmaceutical Ingredients (APIs) and advanced intermediates. The company specialises heavily in manufacturing high-volume bulk drugs for anti-ulcer, anti-fungal, and anti-retroviral therapeutic applications.
Disclaimer
This content is for educational purpose only and the same should not be construed as investment advice. Bajaj Finserv Direct Limited shall not be liable or responsible for any investment decision that you may take based on this content.
Disclaimer
All content and research information displayed on the Site, are obtained from our partner Accord Fintech Private Limited. an authorized data feed vendor of BSE/NSE/MCX/NCDEX exchange. The data is provided on ‘As-Is’ basis and is not a live data feed but a feed with 15 minutes delay or more. Bajaj Markets does not warrant accuracy, completeness, timely availability of the information and data available on the Site. Past performance, when presented, is purely for reference purposes and is not a guarantee of similar future results.
The Services offered on the Site does not constitute investment advice in any manner whatsoever. You shall be solely responsible for any investment decisions made by placing reliance on the information provided on the Site.
Bajaj Markets partners with financial services entities for sourcing leads for services such as DEMAT accounts etc. In case you wish to avail the services, you shall be redirected to partners platform and shall be bound by the terms and conditions, privacy policy governing the said platform.
